News · 26 weeks60-33%
2026-03-012026-08-23
Mix2990d
- SEC Filings14(48%)
- Insider8(28%)
- Other4(14%)
- Earnings2(7%)
- Analyst1(3%)
Latest news
25 items- ANALYSTPersonalis downgraded by Craig Hallum with a new price targetCraig Hallum downgraded Personalis from Buy to Hold and set a new price target of $16.25
- SECPersonalis Inc. filed SEC Form 8-K: Other Events8-K - Personalis, Inc. (0001527753) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Personalis Inc.SCHEDULE 13G/A - Personalis, Inc. (0001527753) (Subject)
- SECSEC Form 10-Q filed by Personalis Inc.10-Q - Personalis, Inc. (0001527753) (Filer)
- SECPersonalis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Personalis, Inc. (0001527753) (Filer)
- PRPersonalis Reports Second Quarter Results and Recent HighlightsClinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments. Second Quarter and Recent Strategic and Operational Highlights Secured Medicare Coverage for IO Monitoring: Received
- SECSEC Form 425 filed by Personalis Inc.425 - Personalis, Inc. (0001527753) (Subject)
- SECSEC Form 8-K filed by Personalis Inc.8-K - Personalis, Inc. (0001527753) (Filer)
- SECSEC Form 425 filed by Personalis Inc.425 - Personalis, Inc. (0001527753) (Subject)
- SECPersonalis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Personalis, Inc. (0001527753) (Filer)
- PRTempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology PlatformAcquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunity Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ:PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ab
- INSIDERPresident and CMO Chen Richard exercised 100,000 shares at a strike of $2.44 and sold $1,515,000 worth of shares (100,000 units at $15.15) as part of a pre-agreed trading plan (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- PRPersonalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great BritainRegulatory milestone for the NeXT Personal® Dx test enables clinical use of Personalis’ ultrasensitive MRD detection in Great BritainPersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that it has achieved UKCA (United Kingdom Conformity Assessed) marking for its NeXT Personal Dx test. This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, encompassing England, Wales, and Scotland.The UKCA marking confirms that the NeXT Personal Dx test meets the United Kingdom's stringent safety, health, and performance standards. This achievement dem
- INSIDERChief Executive Officer Hall Christopher M exercised 100,000 shares at a strike of $1.61 and sold $1,508,000 worth of shares (100,000 units at $15.08) as part of a pre-agreed trading plan (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- SECSEC Form 144 filed by Personalis Inc.144 - Personalis, Inc. (0001527753) (Subject)
- INSIDERCFO AND COO Tachibana Aaron sold $69,748 worth of shares (4,982 units at $14.00) as part of a pre-agreed trading plan and exercised 4,982 shares at a strike of $5.32 (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- SECSEC Form 144 filed by Personalis Inc.144 - Personalis, Inc. (0001527753) (Subject)
- INSIDERCFO AND COO Tachibana Aaron exercised 51,251 shares at a strike of $7.48 and sold $675,488 worth of shares (51,251 units at $13.18) as part of a pre-agreed trading plan (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERChief Executive Officer Hall Christopher M exercised 100,000 shares at a strike of $1.61 and sold $1,315,000 worth of shares (100,000 units at $13.15) as part of a pre-agreed trading plan (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- SECSEC Form 144 filed by Personalis Inc.144 - Personalis, Inc. (0001527753) (Subject)
- SECSEC Form 144 filed by Personalis Inc.144 - Personalis, Inc. (0001527753) (Subject)
- PRPersonalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection KitsRegulatory milestone for specimen collection kits enables global deployment of Personalis' ultrasensitive MRD detection (Next Personal®) for drug development programs Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union's In Vitro Diagnostic Regulation (IVDR). The CE Mark represents an important regulatory milestone, ensuring that clinical trial sites throughout the European Union and Great Britain can use these collection kits for interventional studies. These kits are specific
- INSIDERCFO AND COO Tachibana Aaron exercised 40,000 shares at a strike of $9.16 and sold $480,400 worth of shares (40,000 units at $12.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- SECSEC Form 144 filed by Personalis Inc.144 - Personalis, Inc. (0001527753) (Subject)
- PRPersonalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types Personalis, Inc. (NASDAQ:PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. "Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with Ne
PSNL FAQ
7 questionsWhat does Personalis Inc. do?
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and...Where does PSNL stock trade?
Personalis Inc. (PSNL) is listed on NASDAQ.What sector and industry is PSNL in?
Personalis Inc. operates in the Health Care sector, Medical Specialities industry.When did Personalis Inc. go public?
Personalis Inc. (PSNL) completed its IPO in 2019.What are analysts saying about PSNL?
Personalis Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Hold with a $1625.00 price target on 2026-08-24. Recent price targets range from $600.00 to $2400.00.What companies are similar to PSNL?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare PSNL side-by-side with any of them on Quantisnow.How can I track PSNL on Quantisnow?
Quantisnow aggregates Personalis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PSNL to receive live email and push alerts on every new disclosure.